SCHEMBL4670925

SCHEMBL4670925

O=C(Cc1csc(S(=O)(=O)c2ccc(Cl)cc2)n1)C(=O)c1nn[nH]n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 3/20 0.35
CTPS1 P17812 1/20 0.35
CXCR3 P49682 3/20 0.34
PDE5A O76074 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
MEN1 O00255 2/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 2/20 0.33
POLB P06746 1/20 0.33
TBXA2R P21731 1/20 0.32
NPC1 O15118 1/20 0.31
LMNA P02545 1/20 0.31
AGTR1 P30556 1/20 0.31
HTT P42858 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674830 0.90 ALDH1A1 (0.37) KMT2AALDH1A1CTPS1PDE5AMEN1
SCHEMBL4672470 0.89 KMT2A (0.39) KMT2AALDH1A1CXCR3MEN1SMN1; SMN2
SCHEMBL4672767 0.83 KMT2A (0.39) KMT2AALDH1A1CTPS1PDE5APDE1A
SCHEMBL4678140 0.81 LOXL2 (0.36) KMT2AALDH1A1CXCR3SMN1; SMN2MAPT
SCHEMBL4673305 0.80 CXCR3 (0.35) KMT2AALDH1A1CXCR3MEN1SMN1; SMN2
SCHEMBL4677001 0.80 MAPT (0.40) KMT2AALDH1A1CXCR3SMN1; SMN2MAPT
SCHEMBL4675060 0.79 CXCR3 (0.36) KMT2AALDH1A1CXCR3SMN1; SMN2TBXA2R
SCHEMBL4671618 0.77 ALDH1A1 (0.36) KMT2AALDH1A1CXCR3MEN1SMN1; SMN2
SCHEMBL4675882 0.77 CXCR3 (0.35) KMT2AALDH1A1CXCR3MEN1SMN1; SMN2
SCHEMBL4672179 0.76 LOX (0.37) ALDH1A1CXCR3CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KMT2A 597/4885ALDH1A1 980/4885CTPS1 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.